BioCentury
ARTICLE | Clinical News

FDA approves Teva's Trisenox for newly diagnosed APL

January 19, 2018 7:35 PM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said FDA approved Trisenox arsenic trioxide plus tretinoin to treat adults with newly diagnosed low-risk acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) gene expression.

Trisenox is already approved for induction of remission and consolidation of APL refractory to or relapsed from retinoid and anthracycline chemotherapy, and characterized by the presence of the t(15;17) translocation or PML-RARA gene expression...